5 results about "Amantidine" patented technology

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

The invention relates to the technical field of biological pharmacy, in particular to application of amantadine in preparation of a medicine for treating myocardial injury. It is found for the first time that amantadine can significantly inhibit the activity of cathepsin L and block lysosome-dependent cell death in an inflammatory environment, so that myocardial cell damage is relieved. In-vivo experiments construct an inflammatory myocardial injury mouse model through intramyocardial injection of coxsackie virus B3, and results show that intraperitoneal injection of amantadine effectively inhibits the activity of CTSL in myocardial tissue, remarkably improves the cardiac function of a model mouse, reduces the death rate, and has a good application prospect under the conditions that the virus infection efficiency is not affected and inflammatory cell infiltration of the myocardial tissue is not remarkably reduced. Meanwhile, myocardial fibrosis and pathological cardiac remodeling are relieved. According to the application, amantadine is reported to directly inhibit myocardial cell death in an inflammatory environment instead of playing an indirect myocardial cell protection role through antiviral and anti-inflammatory effects, and a new drug strategy is provided for treatment of inflammatory myocardial injury.

The utility model discloses an easy-to-operate amantadine fluorescent quantitative detection test strip which comprises a connecting plate, fixing plates are uniformly arranged on the upper surface of the connecting plate, a positioning block is arranged above the fixing plates, a sampling tube is arranged on the inner side of the positioning block, limiting plates are uniformly arranged on the inner side of the connecting plate, and the limiting plates are arranged on the inner side of the connecting plate. The limiting plate and the connecting plate are clamped through elastic balls, a placing plate is arranged on the inner side of the limiting plate, a placing groove is formed in the upper surface of the placing plate, a handle is arranged at one end of the placing plate, sliding grooves are formed in the two sides of one end of the placing plate, and moving blocks are arranged on the inner sides of the sliding grooves; a limiting groove is formed in the inner side of the moving block, a protective pad is arranged on the inner surface of the limiting groove, the moving block is slidably connected with the sliding groove through a positioning strip, and a detection hole is formed in the upper surface of the limiting plate. The amantadine fluorescence detection device is convenient for workers to operate, and the amantadine fluorescence detection efficiency is improved.

The application discloses a compound acetaminophen and amphetamine capsule containing caffeine microcapsules, and relates to the technical field of medicines. The capsule comprises acetaminophen, amantadine hydrochloride, artificial bezoar, medicinal excipients and a functional microcapsule unit. The functional microcapsule unit has a three-layer structure, i.e. a core material with caffeine and microcrystalline cellulose, an ethyl cellulose controlled-release layer and a rapid-release layer containing chlorpheniramine maleate. The structure realizes time sequence controlled release of the drugs through synthesis of a high-molecular coating material: the chlorpheniramine maleate is rapidly released in the gastrointestinal fluid to quickly resist allergy, and the caffeine is effectively delayed to start slow release in the intestinal environment, so that the blood drug concentration peak time of the caffeine is synchronized with that of the chlorpheniramine maleate, and the side effect of drowsiness is more effectively resisted.